Weight Loss Injections in India: The Complete 2026 Guide

Quick answer: Weight loss injections available in India are GLP-1 receptor agonists — semaglutide (Wegovy, Ozempic and generics) and tirzepatide (Mounjaro), plus older liraglutide (Saxenda). All are prescription-only Schedule H drugs. In trials, semaglutide 2.4 mg produced a mean 14.9% body-weight reduction over 68 weeks and tirzepatide up to 20.9% over 72 weeks. None works without a clinician assessing whether it is appropriate for you.

What actually counts as a "weight loss injection"?

The phrase covers one family of medicines: GLP-1 receptor agonists. They imitate a gut hormone your body already makes after eating, which signals fullness to the brain and slows how quickly the stomach empties. The result is that you feel satisfied earlier and stay satisfied longer — not that fat is burned directly.

This distinction matters. These are appetite and metabolic medicines, not fat-dissolving injections. Anything marketed as a "fat dissolving injection" for general weight loss is a different and largely unevidenced category, and you should treat those claims with real suspicion.

What is available in India in 2026

• Tirzepatide (Mounjaro) — a dual GIP/GLP-1 agonist, the most effective option in head-to-head evidence. Weekly injection.
• Semaglutide (Wegovy, Ozempic, and generics since the 2026 patent expiry) — weekly injection. Wegovy is the weight-management formulation; Ozempic is the diabetes formulation of the same molecule.
• Liraglutide (Saxenda) — an older daily injection, largely superseded by the weekly options but still prescribed in some cases.
• Oral semaglutide (Rybelsus) — a daily tablet, not an injection, approved in India for type 2 diabetes.

How much weight do they actually cause?

The honest numbers, from the registration trials:

• Semaglutide 2.4 mg: mean 14.9% body-weight reduction at 68 weeks in adults with overweight or obesity without diabetes.
• Tirzepatide: mean reductions of roughly 15% to 21% at 72 weeks depending on dose.
• Both, if you have type 2 diabetes: meaningfully less. In the STEP 2 trial, semaglutide produced smaller reductions in people with type 2 diabetes than in those without.

Those are averages across thousands of people. Some lose considerably more, some considerably less, and a minority respond poorly. Any clinic quoting you a guaranteed number is overselling.

What they cost in India

Cost is the single biggest factor Indian patients weigh, and it changed sharply when semaglutide's patent expired in 2026 and generics entered the market. Branded tirzepatide remains the most expensive option; generic semaglutide is now dramatically cheaper than either brand. Because pricing is moving quickly, confirm current figures with your pharmacy or care team rather than relying on any article, including this one.

One thing worth understanding: at MetaFit the programme fee and the medication cost are separate. The subscription covers clinical supervision, coaching and the app; medication is prescribed only where clinically appropriate and billed at cost, with no markup.

Who is eligible?

Eligibility is a clinical decision, but the general framing is that these medicines are for people whose weight is causing or threatening health problems — not for cosmetic weight loss in people at a healthy weight. Indian bodies develop metabolic complications at lower BMIs than European populations, which is why a WHO expert consultation identified 23 kg/m² as a public-health action point for Asian populations rather than the conventional 25 or 30.

A proper assessment looks at your BMI and waist circumference, blood glucose and HbA1c, thyroid function, lipids, personal and family medical history, and current medications.

What these medicines do beyond weight

This is the part most cost comparisons miss. In the SELECT trial, semaglutide reduced major adverse cardiovascular events by 20% in people with overweight or obesity and established cardiovascular disease but without diabetes. Tirzepatide has been shown to improve obstructive sleep apnoea, and semaglutide to reduce knee osteoarthritis pain in people with obesity.

The honest downsides

Gastrointestinal side effects — nausea, constipation, reflux — are common, usually worst during dose escalation, and are the most frequent reason people stop. There is an increased risk of gallbladder disease. And crucially, the effect depends on continued treatment: when semaglutide was withdrawn in the STEP 1 trial extension, participants regained roughly two-thirds of the weight they had lost within a year.

That last point should shape your expectations before you start. This is management of a chronic condition, not a course of antibiotics.

How to decide

Get assessed before you get attached to a particular drug. The right question is rarely "which is strongest" — it is which one you will tolerate, afford and stay on for twelve to eighteen months, alongside the protein intake and resistance training that protect your muscle while you lose fat.